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inclusion of large numbers of patients with a good progconfounded by the variable course of the disease and, in nosis has been one of the major weaknesses of previous particular, by the frequent development of spontaneous clinical trials of therapy in membranous nephropathy.
remissions, sometimes many months or years after the In a recent update that compares the Canadian data onset of NS, reported in studies of natural history [4] [5] [6] , to other patient populations in Italy and Finland, the 20]. Treatment may be considered in two broad categopredictive model outlined above has been validated [12] .
ries: the management of symptoms and signs of NS (for The most important factor determining long-term outexample, edema, hyperlipidemia) and therapies aimed come in membranous nephropathy was found to be the at inducing remission of proteinuria and preventing prohighest sustained six-month period of proteinuria. The gression to ESRD. model was able to predict patients at high risk of progresThromboembolic complications, especially renal vein sion with an accuracy of more than 85%, despite the thrombosis, are frequent in NS in general and membradifferences at baseline.
nous nephropathy in particular. The incidence of renal A number of studies have examined the natural history vein thrombosis in membranous nephropathy has been and outcome of membranous nephropathy, with or withreported at 5 to 60% [21] [22] [23] . This wide range reflects a out therapy [4] [5] [6] [13] [14] [15] . Honkanen, Tornroth and Gronhigh incidence of subclinical thrombosis, identified by hagen-Riska, in a recent review, suggested that overall prophylactic venography [22] . Routine use of prophylacpatient survival was approximately 83% at 10 years comtic anticoagulation has not been the norm in most centers pared with 88% for an age-and sex-matched Finnish [23, 24] . However, an article by Sarasin and Schifferli control population [13] . Other studies have reported simsuggested, using a decision model, that the benefits of ilar long-term survival. For patients with NS, Honkanen prophylactic anticoagulation outweighed the risks and et al reported a 10-year survival of 70%, irrespective of that it should be routine for all patients with NS secondthe treatment given [13] .
ary to idiopathic membranous nephropathy [25] . ProphySchieppati et al reported on the course in 100 patients lactic anticoagulation should certainly be considered in who received no therapy other than supportive treatpatients felt to be at high risk for venous thrombosis, ment [6] . The incidence of remission of proteinuria inthat is, those with severe or prolonged nephrotic range creased over time such that at five years, 65% were in proteinuria. This has not yet been subjected to a randomcomplete or partial remission, whereas only 16% proized controlled trial. A firm recommendation thus cannot gressed to end-stage renal disease (ESRD). The benign be made. course of these patients may, in part, be explained by Over the past 30 years, many different treatment regithe modest degree of proteinuria. Fully 37% had nonnemens have been recommended for the treatment of idiophrotic-range proteinuria (that is, less than 3.5 g/day), pathic membranous nephropathy. The heterogeneity of whereas 56% had less than 5 g/day. study designs, treatment regimens, enrollment criteria, In contrast, the prognosis of membranous nephropaoutcomes, and follow-up data has lead to considerable thy seems to be much more benign in women, children, difficulty in interpreting the results of these many studies. younger adults, and those with secondary (drug-induced)
There are a number of prospective, randomized trials disease [8, [16] [17] [18] . Patients in whom proteinuria is less addressing a variety of treatment regimens, but with very than 3.5 g/day or who maintain normal renal function variable results. The lack of consistent results favoring for the first three years also have a good prognosis [4] . one treatment over another is what lies behind the current debate on the optimal treatment of idiopathic mem-METHODS branous nephropathy. This article focuses on a critical review of the extensive published literature in the area, with an emphasis on the Recommendations levels of evidence for the validity of the studies cited, Recommendation 1. There is no benefit of either a using the guidelines developed by Carruthers et al for short or prolonged course of oral, alternate-day steroids studies of treatment [19] . A total of more than 200 artifor either inducing remission of NS or preserving renal cles was identified from a MEDLINE search covering function in patients with membranous nephropathy. Cortithe period from 1970 to 1997, using the key words memcosteroids should not be used as sole therapy (grade A). branous nephropathy and therapy. Abstracts were reEvidence. There have been three large, prospective, viewed and articles selected for in-depth review using randomized, placebo-controlled clinical trials (RCTs) of the criteria proposed by Carruthers et al [19] .
corticosteroid therapy for membranous nephropathy (Table 1) published between 1979 and 1990 [26] [27] [28] . These MANAGEMENT OF IDIOPATHIC studies are comparable in terms of the clinical and demo-MEMBRANOUS NEPHROPATHY graphic characteristics of the patients. End points were similar, although there were differences in the definitions Evaluation of the effectiveness of treatment strategies for idiopathic membranous nephropathy is substantially of partial and complete remissions of the NS. [26] , the smallest of the three RCTs, reported that a minimum of eight weeks of high-dose (100 phropathy [31] . This observation is, as yet, unconfirmed. Recommendation 3. Treatment with alkylating agents to 150 mg, depending on body weight), alternate-day prednisone resulted in a significant reduction in the rate of induces prolonged remission of membranous nephropathy. Because most controlled trials have used corticosteprogression to renal failure. The short follow-up period and poorer than expected outcome in the placebo group roids in combination with alkylating agents, it is recommended that both be used. Specific recommendations [4, 5] have led to criticism of the results of this study. However, some authors continue to recommend this reregarding timing, dose, and duration of therapy are provided in Table 2 and Figure 1 . Given the potential toxicity gime for patients with early histological disease and persistent NS, despite the lack of any evidence for benefit, of these therapies, they should be reserved for patients at high risk of progression to renal failure (grade A). citing the relative safety of therapy as justification [7] .
The British Medical Research Trial [27] duplicated Evidence. Despite the widespread use of cyclophosphamide and chlorambucil in patients with idiopathic the effort of the U.S. study but with a larger patient population and a longer duration of follow-up (minimum membranous nephropathy, the clinical trial evidence on which these treatments are based consists of a number of 3 years). This study was unable to demonstrate any significant effect of a short course of corticosteroids on of small uncontrolled studies [32] [33] [34] [35] [36] and just six prospective RCTs [37] [38] [39] [40] [41] [42] , which vary in study design, entry renal function or urinary protein excretion at three years, although there was a modest early beneficial effect on criteria, and outcomes evaluated ( Table 2) . Many of the smaller trials suffer from significant methurinary protein excretion and serum albumin noted at three to six months. odological flaws, in that they are either retrospective or lack the statistical power, because of sample size considThe study of the Toronto Glomerulonephritis Study Group evaluated a much longer (six months) course of erations, to allow firm conclusions to be drawn. As such, the data presented in these studies must be interpreted oral, alternate-day prednisone in a lower dose (45 mg/m 2 ) than the earlier studies on the outcome of idiopathic with caution. However, Lagrue et al, in a retrospective study, noted complete or partial remission of proteinuria membranous nephropathy [28] . After a median followup period of 48 months, there was no difference in the in 13 out of 16 patients with membranous nephropathy who were treated with chlorambucil compared with just rates of decline in creatinine clearance or in the proportions of patients in either partial or complete remission.
3 out of 14 on placebo and 1 out of 11 on azathioprine [32] . In contrast, neither Shearman et al nor Alexopoulos No early benefits were noted.
Recommendation 2. Azathioprine should not be used et al found any benefits from oral cyclophosphamide compared with either corticosteroids or symptomatic as part of routine care for this condition (grade C).
Evidence. Few studies have addressed the effects of therapy in their retrospective studies [35, 36] . Donadio et al conducted a study of 22 patients ranazathioprine either alone or in combination with steroids in membranous nephropathy. Those that have addressed domized to either oral cyclophosphamide of 1.5 to 2.5 mg/kg daily or no specific therapy for a period of 12 these effects suggest that it is largely ineffective in either inducing remission of NS or preventing renal insuffimonths [37] . There was no effect of cyclophosphamide on renal function, proteinuria, or histological stage of ciency [29, 30] . A recent uncontrolled study did, however, suggest that the addition of oral azathioprine to a regime disease. Falk et al conducted a randomized controlled trial of intravenous and oral corticosteroids plus intraveof intravenous pulse methylprednisolone and oral pred- nous cyclophosphamide compared with oral corticosterate studies of chlorambucil in the treatment of idiopathic membranous nephropathy. The first of these, pubroids alone in 26 patients with idiopathic membranous nephropathy and clinical and laboratory evidence of delished in 1984, was a RCT of six months treatment with chlorambucil plus corticosteroids in monthly cycles verterioration [38] . Over a mean follow-up period of 29.2 Ϯ 17.1 months, there were no differences between the rate sus symptomatic therapy, in patients with nephrotic range proteinuria related to idiopathic membranous neof progression to ESRD (4 out of 13 in each group) nor in the severity of renal failure or urinary protein phropathy [39] . Impressive results favoring the treatment group were reported, with 23 out of 32 chlorambucil excretion. West et al conducted a case-control study of oral cyclophosphamide versus oral corticosteroids (in 15 patients experiencing a complete or partial remission compared with just 9 out of 30 control patients. The out of 17 control subjects) in idiopathic membranous nephropathy [40] . They were able to conclude that thersecond study, published in 1992, compared the chlorambucil/steroid regimen with steroids alone in 92 nephrotic apy with cyclophosphamide was associated with improvement in both serum albumin and 24-hour proteinuria, patients with idiopathic membranous nephropathy [42] . None of the patients had participated in the earlier study. while preserving renal function and delaying progression to ESRD. This study is remarkable for its selection of a Again, a net benefit favoring the chlorambucil-treated patients was apparent, both for remission of NS (66% group of patients at high risk for progression, that is, persistent proteinuria of more than 3.5 g/day and serum free of NS at three years vs. 40% in control) and preservation of renal function. This study suggested that treatcreatinine of more than 135 mol/liter.
Murphy et al studied 40 patients randomized to either ment with chlorambucil/methylprednisone was less likely to induce a remission in the presence of renal insuffino specific therapy or a treatment regimen consisting of oral cyclophosphamide for six months and oral warfarin ciency or mesangial sclerosis. Ponticelli et al have recently published data concernand dipyridamole for two years [41] . Renal function was unchanged during two years of follow-up in both groups, ing 10-year outcomes in their original cohort of 81 patients prospectively randomized to symptomatic therapy but reduced proteinuria and improved serum albumin were found in the cyclophosphamide-treated patients.
compared with cyclic treatment with intravenous methylprednisolone, oral prednisone, and oral chlorambucil When only those patients with the NS are considered, a significantly higher proportion of patients in the treat- [43] . All of these patients had NS at the time of initial treatment assignment, in contrast to other prospective ment group achieved a complete remission compared with control patients (9 out of 13 vs. 4 out of 13, P ϭ 0.05).
studies and to studies of untreated patients, in which a variable percentage of patients had non-nephrotic proPonticelli et al have published the results of two sepa- teinuria. Ten-year follow-up revealed that the probabilwith renal insufficiency were not excluded [28] . The 10-year renal survival of 72% reported by Schieppati in ity of renal survival was 0.92 (95% CI, 0.83 to 1.00) for treated patients compared with 0.60 (95% CI, 0.42 to untreated patients from the same region of Italy as Ponticelli's patients must be interpreted with caution, as 37% 0.78) for controls. This raises the question of whether Ponticelli's control patients may have experienced an of their patients had nonnephrotic range proteinuria and 56% had less than 5 g/day of proteinuria [6] . Massive unduly rapid progression of renal failure. In contrast, Cattran et al reported an actuarial survival, using a creatiproteinuria has been identified in a number of studies as an important risk factor for progression [4, 8] , alnine clearance of 0.16 ml/seconds as the end point, of 91 versus 90% at eight years for control versus prednisonethough the recent meta-analyses have failed to demonstrate this as an independent risk factor, perhaps because treated patients [28] . Cattran et al's patients were very similar to Ponticelli's in all respects except that patients of methodological limitations. The relative rarity of mas- sive proteinuria (only 10% of patients had proteinuria progression [49]. Of 64 patients followed initially on a low-protein diet, 17 had persistent nephrotic range proin excess of 10 g/day) may further explain the relatively benign course undergone by the patients described by teinuria and a rate of decline in creatinine clearance in excess of 8 ml/min/year, and were randomized to cycloSchieppati et al [6] .
Several small studies have examined the effects of sporine or placebo. After 12 months of drug therapy, patients on cyclosporine had a significantly slower rate chlorambucil or cyclophosphamide on the outcome of membranous nephropathy in patients with more advanced of decline in renal function and less proteinuria than placebo-treated patients. These benefits persisted for up disease [44, 45] . In both of these studies, patients had severe and/or persistent NS (24-hr protein of more than to two years after the withdrawal of cyclosporine. These results are certainly encouraging, but will need to be 3.5 g for more than six months) and renal insufficiency (serum creatinine of more than 159 mol/liter) prior to confirmed by a larger trial with a more prolonged followup period, given the natural history of the disease. cytotoxic therapy. Both treatments have been associated with an improvement in both the degree of proteinuria Meta-analyses of studies in idiopathic and rate of decline in renal function despite the presence membranous nephropathy of advanced histological disease, severe proteinuria, and renal failure. This observation is important, as most of Two meta-analyses of clinical trials in idiopathic membranous nephropathy have recently been published [50, the patients in the RCTs of both chlorambucil and cyclophosphamide had normal renal function prior to treat-51]. Imperiale, Goldfarb, and Berns conducted a detailed examination of the five randomized prospective clinical ment. It may be that patients selected on the basis of a higher risk of progression will be more likely to benefit trials of cyclophosphamide and/or chlorambucil in this disease [50] . In contrast to the often very large numbers from alkylating agents. However, this remains to be studied in a clinical trial of adequate size and duration. of patients reported in retrospective studies focused either on therapy or natural history, these five studies Recommendation 4. Cyclosporine therapy shows promise as an effective therapy for patients with membranous collectively involve just 228 patients. Even in this small group of studies, there is still considerable heterogeneity nephropathy who are at high risk for progressive renal failure (grade B). Cyclosporine of 4 to 6 mg/kg daily for in the doses and duration of drug therapy, mean duration of follow-up, definitions of complete and partial re-12 months is the preferred regimen.
Evidence. A number of trials have addressed the use sponses to treatment and comparison therapies used. However, despite these shortcomings, this meta-analysis of cyclosporine, usually in conjunction with steroids, for the treatment of idiopathic membranous nephropathy provides evidence suggesting that, for some patients at least, there are benefits to the use of alkylating agents. (Table 3) , as well as membranous lupus nephritis [46] [47] [48] [49] . The usual dose of cyclosporine used in these studies has For all of the trials, the relative risk (RR) of achieving a complete remission in the treatment group (urine probeen 4 to 6 mg/kg. The majority of studies have been uncontrolled yet have shown promising results with retein of less than 0.2 to 0.5 g/day) was 4.6 (95% CI, 3.2 to 8.4). When just the RCTs were included in the metaspect to both remission of NS and preservation of renal function, together with freedom from serious cyclosporine analysis, the RR was 3.4 (95% CI, 1.6 to 7.1). There were no qualitative or quantitative differences noted in nephrotoxicity.
Cattran et al recently reported the results of a randomcomplete remission rates for cyclophosphamide compared with chlorambucil treatment. Calculation of the ized trial of cyclosporine in patients with idiopathic membranous nephropathy who were felt to be at high risk of number needed to treat (NNT) to produce one complete lack of clear renal outcome data in the source material.
• Intravenous pulse cyclosphosphamide should not be used • Cycle repeated ϫ three for a total duration of six months [39, analysis of the prospective trials noted earlier here, as 42] .
well as pooled analyses, including many retrospective
• Chlorambucil dose should be adjusted to maintain total WBC Ͼ 4.5 ϫ 10 9 /liter. studies and case series for which relevant outcome data
The dose of both cyclophosphamide and chlorambucil should could be gleaned from the published articles. In this way, be based on an estimate of 'dry' or pre-nephrotic weight to the analysis was able to include data on close to 2000 avoid marrow toxicity. 3. Cyclosporine patients followed, in most cases, for more than two years.
• 4 to 6 mg/kg/day in two divided doses for six to twelve months
The meta-analysis again found that the RR for complete [46] [47] [48] [49] . Dose should be adjusted to maintain monoclonal whole remission in patients treated with alkylating agents was blood trough level of 120 to 200 ng/ml.
• Prednisone 1 to 2 mg/kg on alternate days may be added [46] [47] [48] 4.8 (95% CI, 1.44 to 15.96). The results of the pooled as above, but should be tapered as soon as a response is evident.
analysis revealed that renal survival, however, was no Abbreviations are: WBC, white blood cells; i.v., intravenous. different at two years between alkylating therapy and either the symptomatic therapy or steroid groups. At five years, there was a lower probability of renal survival CONCLUSIONS in the steroid/no-therapy group (0.80) than in patients receiving alkylating agents (0.99).
Despite the large number of clinical studies with variable outcome measures and treatment regimes, it is posToxicity of cytotoxic therapy sible to draw some reasonably firm conclusions (Table The conclusions that can be drawn from studies of 4 and Fig. 1 ). First, data from the three randomized controlled trials suggest that, on balance, there is no cytotoxic therapy for membranous nephropathy are necjustification for the continued use of corticosteroids essarily tempered by concern regarding the potential alone as primary therapy for patients with NS caused by toxicities of both chlorambucil and cyclophosphamide, idiopathic membranous nephropathy. There is even less as well as continued anxiety concerning the long-term justification to use corticosteroids in patients without NS. outcome of therapy. Although Ponticelli et al's most Second, the spontaneous favorable outcome in many recent follow-up study may allay the latter fear [43, 52] , patients with idiopathic membranous nephropathy and many physicians remain reluctant to commit their pa-NS, with up to 40% of patients entering complete remistients to cytotoxic therapy, preferring to use corticostesion, often delayed, does not justify the routine use of roids despite clear evidence that they are ineffectual.
cytotoxic therapy for all patients even with NS. However, A recent article highlighted the potential long-term a meta-analysis of the RCTs of cytotoxic therapy for consequences of cyclophosphamide therapy. Talar-Wilmembranous nephropathy indicates that there are longliams et al evaluated the occurrence of bladder cancer term benefits on both the remission of NS and the rate in patients who had received cyclophosphamide as therof progression of renal failure. Cytotoxic therapy should apy for Wegener's granulomatosis at the National Institherefore be offered to all patients who are felt to be at tutes of Health between 1967 and 1993 [53] . They found high risk of progression based on clinical factors such as that prolonged cyclophosphamide therapy, particularly age, male gender, renal function, blood pressure, severity at cumulative doses in excess of 100 g, was associated and persistence of NS, or histological presence of severe with an increased rate of development of bladder cancer.
tubulointerstitial disease. Meta-analysis of RCTs does The bladder cancer risk was estimated to be 5% at 10 not indicate a preference for chlorambucil over cycloyears and 16% at 16 years after first exposure to cyclophosphamide. The recent publication by Ponticelli et al phosphamide. A cumulative dose of 100 g requires some of a randomized comparison of cyclophosphamide versus 19 months of therapy for a 70 g patient on 2.5 mg/kg chlorambucil suggests that the therapies should be condaily. It remains to be seen what effect, if any, this finding sidered equivalent in terms of efficacy [52] . Both drugs will have on the use of cyclophosphamide for glomerular are associated with significant short-and long-term toxicity. The recent report of a significant increase in the risk diseases of all kinds. scale trials confirm efficacy, cyclosporine has the poten- 
